Eyebio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.

Sonothera is developing ultrasound-guided nonviral genetic therapies.

Elevate Bio is a technology-driven cell and gene therapy company that accelerates access to cutting-edge technologies and expertise to transform medicine. Founded in 2017, the company integrates multiple R&D technology platforms, including Life Edit for gene editing, and Base Camp for cGMP manufacturing, to enable the development of a wide range of cell and gene therapies. Elevate Bio partners with industry leaders and academic institutions to streamline the process from research to commercialization, positioning itself as a key player in the rapidly evolving genetic medicines market.

Septerna is a clinical-stage biotechnology company pioneering GPCR drug discovery through its proprietary Native Complex Platform™, focusing on developing oral small molecule therapies for endocrinology, immunology, inflammation, and metabolic diseases. The company aims to unlock the potential of difficult-to-drug GPCRs, advancing a deep pipeline of drug candidates to address significant unmet medical needs. With a world-class team of experts, Septerna is positioned to make a substantial impact in the biotechnology sector, leveraging cutting-edge science and collaboration to drive innovation and results.

Sonoma Biotherapeutics is developing engineered regulatory T cell (TREG) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in TREG biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted TREG cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.

Spy Glass Pharma™ is a privately-held ophthalmic biotechnology company focused on developing a controlled release drug delivery platform for glaucoma treatment. Their innovative technology allows for the sustained delivery of bimatoprost over multiple years, addressing the critical issue of patient non-adherence to glaucoma medications. The platform is designed to be implanted during routine cataract surgery, making it a versatile solution for millions of glaucoma patients. With a strong leadership team and ongoing clinical trials, Spy Glass Pharma is positioned to make a significant impact in the ophthalmic market.

Earlens Corporation is a privately held medical device company committed to providing hearing impaired patients with a state-of-the-art hearing solution that is designed to change the current standard of care for sound performance.

Obsidian Therapeutics is pioneering engineered cell and gene therapies using its proprietary cyto DRi VE® platform to develop precision medicines. The company focuses on creating adoptive immunotherapies, particularly through its lead clinical program OBX-115, which has received FDA designations for advanced melanoma treatment. Their innovative approach allows for controlled protein activity in cells, enhancing the efficacy of cell therapies. With a strong pipeline and collaborations with major partners, Obsidian is positioned to make significant impacts in oncology and improve patient outcomes.

Neumora Therapeutics is a clinical-stage biotechnology company focused on pioneering precision medicines for brain diseases. The company addresses the significant challenge of developing targeted and effective treatments for neuropsychiatric and neurodegenerative disorders, which affect over 1.5 billion people globally. Neumora's innovative approach involves targeting novel mechanisms of action with best-in-class pharmacology, supported by a Precision Toolbox that integrates translational, clinical, and computational tools. This commitment to understanding the biological drivers of brain diseases positions Neumora as a leader in the neuroscience drug development space, aiming to meet the high unmet medical needs of patients.

Moximed is a pioneering medical device company focused on enhancing care for patients suffering from osteoarthritis through its innovative MISHA Knee System. This implantable shock absorber (ISA) is designed for patients with medial knee osteoarthritis who have not found relief from other treatments and are not candidates for knee replacement. The MISHA Knee System aims to improve patient outcomes by providing a quick recovery time and clinically meaningful pain relief, positioning Moximed as a leader in the orthopedic market. With strong clinical results and a commitment to patient care, Moximed is well-positioned for growth in the medical device industry.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision-guided therapeutics, particularly for solid tumors. Their unique Bicycle technology allows for targeted delivery of therapies, addressing significant unmet medical needs in oncology and beyond. The company collaborates with various pharmaceutical partners to explore applications in multiple therapeutic areas, including anti-infective and cardiovascular diseases. With a strong pipeline and innovative approach, Bicycle aims to transform patient outcomes and establish itself as a leader in the biopharmaceutical industry.

Nuvaira, Inc. is a privately held medical device company focused on developing innovative therapies for obstructive lung diseases, particularly Chronic Obstructive Pulmonary Disease (COPD). Their flagship product, the d Nerva® Lung Denervation System, is a catheter-based system designed to treat overactive airway nerves through a one-time outpatient procedure, aiming to reduce the frequency and severity of COPD exacerbations. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira has achieved significant milestones, including over 500 active treatments and recognition as a Breakthrough Device by the FDA. With a strong patent portfolio and ongoing clinical investigations, Nuvaira is positioned to transform the standard of care for millions affected by COPD.